Market Snapshot
S&P Futures
3,914.75
Dow Futures
31,478
Nasdaq Futures
12,132.75
INmune Bio, Inc. (INMB) stock rallied over 11.04% intraday to trade at $8.25 a share on NASDAQ. The stock opened with a gain of 15.06% at $7.47 and touched an intraday high of $8.802, rising 11.04% against the last close of $7.43. The stock went to a low of $7.47 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-23 | $7.47 | $8.802 | $7.47 | $8.25 | 162,200 |
2022-06-22 | $7.17 | $7.7 | $7.1 | $7.43 | 70,500 |
2022-06-21 | $7.15 | $7.56 | $7.11 | $7.22 | 63,200 |
2022-06-17 | $6.8 | $7.48 | $6.792 | $7.08 | 98,300 |
2022-06-16 | $6.76 | $6.91 | $6.25 | $6.73 | 109,700 |
2022-06-15 | $6.91 | $7.17 | $6.72 | $6.96 | 27,100 |
2022-06-14 | $6.6 | $7 | $6.56 | $6.82 | 51,900 |
2022-06-13 | $7.35 | $7.46 | $6.5 | $6.66 | 101,600 |
2022-06-10 | $7.65 | $7.763 | $7.275 | $7.52 | 92,100 |
2022-06-09 | $7.24 | $8 | $7.15 | $7.92 | 95,100 |
Employees-
Beta2.31
Sales or Revenue181 Thousands
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INmune Bio, Inc. (NASDAQ: INMB) stock price is $8.25 as of the last check on Thursday, June 23. During the trading session, INMB stock reached the peak price of $8.802 while $7.47 was the lowest point it dropped to.
The NASDAQ listed INMB is part of Biotechnology industry that operates in the broader Health Care sector. INmune Bio, Inc. , a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease.
Dr. Raymond Joseph Tesi M.D.
Co-Founder, Pres, CEO, Chief Medical Officer & Chairman
Mr. David J. Moss M.B.A.
CFO, Treasurer & Sec.
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.
Chief Scientific Officer & Chief Manufacturing Officer
Mr. Joshua S. Schoonover Esq.
Assoc. Gen. Counsel
INMB stock traded closed the last session at $8.25, which is $0.82 or 11.04% lower than its previous close of $7.43. INMB's current trading price is 78.23% lower than its 52-week high of $30.37 where as its distance from 52-week low of 4.63% is -72.84%.
Number of INMB employees currently stands at -. INMB operates from 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL 33432, United States.
Official Webiste of $INMB is: https://www.inmunebio.com
INMB could be contacted at INMB operates from 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL 33432, United States, or at phone #858 964 3720 and can also be accessed through its website.
INMB stock volume for the day was 162,249 shares while in the previous session number of INMB shares traded was 162,200 . The average number of INMB shares traded daily for last 3 months was 139.02 Thousands.
The percentage change in INMB stock occurred in the recent session was 11.04% while the dollar amount for the price change in INMB stock was $0.82.
In the recent session, the day high for INMB stock was $8.802 while the low for INMB stock touched on the day was $7.47.
The market value of INMB currently stands at 140.74 Million with its latest stock price at $8.25 and 17.87 Million of its shares outstanding.